

InnoCan Pharma

08:55 09 Jul 2020

InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes

InnoCan Pharma Corporation (CNSX:INNO) announced Thursday it is collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes.

In layman's terms, exosomes are extracellular vesicles, crucial in cell-to-cell communication which are being explored as a means of drug delivery. Also, the small vesicles that are created when stem cells are multiplied can target and help repair damaged cells.

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees.

READ: InnoCan Pharma inks deal securing CBD for its coronavirus treatment collaboration with Tel Aviv University and other R&D projects

Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas -- pharmaceutical development services and manufacturing service.

InnoCan said Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

"Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm," InnoCan CEO Iris Bincovich said in a statement.

Potential for different formulations

Dr Sylvia Kachalsky, site manager for Recipharm in Israel, said the project has the potential to be applied to a large spectrum of different indications.

"The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a 'targeted missile' leading the chosen Cannabinoid to its target," she added.

Professor Daniel Offen, who is leading InnoCan's research, said the project will look to produce exosomes with CBD, adding that "the development of the CLX- CBD loaded Exosome is very challenging but holding huge potential."

Israel-based InnoCan has previously stated that the exosomes could be used as treatments for coronavirus (COVID-19) and central nervous system disorders.

Contact the author: patrick@proactiveinvestors.com

Price: 0.275

Market Cap: \$48.32 m

1 Year Share Price Graph



December 2019 June 2020 November 20

Share Information

Code: INNO

Listing: CSE

52 week High Low
0.35 0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).